---
figid: PMC5746412__oncotarget-08-110656-g005
figtitle: PKM2 in carcinogenesis and oncotherapy
organisms:
- NA
pmcid: PMC5746412
filename: oncotarget-08-110656-g005.jpg
figlink: /pmc/articles/PMC5746412/figure/F5/
number: F5
caption: (A) Shikonin inhibit TPA-induced neoplastic cell transformation and PKM2
  to suppress aerobic glycolysis. (B) Selumetinib as an MEK's inhibitor decreases
  the expression of PKM2 and the production of lactic acid to suppress tumor cell
  proliferation. (C) TRIM35 interacts with the coiled-coil domain of PKM2 to alleviate
  the tumor cell proliferation. (D) FFJ-5 and FFJ-3 down-regulate PKM2 to inhibit
  cancer cell growth. (E) OA alternatively splices PKM transcriptional initial mRNA
  and AIC-47 disrupts Bcr-abl/mTOR/hnRNP signaling pathway to produce more PKM1 and
  abolish Warburg effect. (F) shRNA is used to knockdown PKM2 gene with PKM1 substitution
  for suppressing Warburg effect. (G) siRNAs is used to silence PKM2 gene for the
  inhibition of tumor cells.
papertitle: PKM2 in carcinogenesis and oncotherapy.
reftext: Xia He, et al. Oncotarget. 2017 Dec 15;8(66):110656-110670.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9182138
figid_alias: PMC5746412__F5
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC5746412__F5
ndex: 29c4fb47-df0f-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5746412__oncotarget-08-110656-g005.html
  '@type': Dataset
  description: (A) Shikonin inhibit TPA-induced neoplastic cell transformation and
    PKM2 to suppress aerobic glycolysis. (B) Selumetinib as an MEK's inhibitor decreases
    the expression of PKM2 and the production of lactic acid to suppress tumor cell
    proliferation. (C) TRIM35 interacts with the coiled-coil domain of PKM2 to alleviate
    the tumor cell proliferation. (D) FFJ-5 and FFJ-3 down-regulate PKM2 to inhibit
    cancer cell growth. (E) OA alternatively splices PKM transcriptional initial mRNA
    and AIC-47 disrupts Bcr-abl/mTOR/hnRNP signaling pathway to produce more PKM1
    and abolish Warburg effect. (F) shRNA is used to knockdown PKM2 gene with PKM1
    substitution for suppressing Warburg effect. (G) siRNAs is used to silence PKM2
    gene for the inhibition of tumor cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Egfr
  - Mtor
  - Tor
  - Myc
  - pkm
  - PyK
  - pk
  - Decay
  - Parp
  - TRIM35
  - PKM
  - PKLR
  - HADHA
  - PLAT
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - EGFR
  - MTOR
  - HNRNPC
  - HNRNPDL
  - MYC
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - Selumetinib
  - Oleanolic acid
  - Cancer
---
